What is the 13F Pro Quality Score for COLL?

13F Pro ranks COLLEGIUM PHARMACEUTICAL, INC (COLL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COLL's current score at https://13fpro.ai/company/COLL (free sign-up required for the full ranking).

Which hedge funds own the most COLL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of COLL include BlackRock,, Jupiter Topco, Invesco Ltd.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/COLL as soon as new 13F filings post.

Where does 13F Pro source COLL data?

All COLLEGIUM PHARMACEUTICAL, INC fundamentals and ownership data come directly from SEC EDGAR. COLLEGIUM PHARMACEUTICAL, INC files with the SEC under CIK 1267565. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COLL in?

COLLEGIUM PHARMACEUTICAL, INC (COLL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COLL research updated on 13F Pro?

COLL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

COLLEGIUM PHARMACEUTICAL, INC(COLL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1267565 COLL stock profile & AI dashboard →

13F Pro Quality Score

62.7/100

Rank #692 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.7/100

Profitability

54.3/100

Balance Sheet

56.8/100

Earnings Quality

97.4/100

Free Cash Flow

91.0/100

Institutional Flow

23.6/100

Revenue Scale

46.2/100

Dilution Risk

24.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why COLL Scores 63/100

exact factor attribution · 2026-09-11

COLL's composite is driven by free cash flow and revenue growth, held back by earnings growth and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+6.2 pts

91th pct

Revenue growth

+5.5 pts

78th pct

Earnings quality

+4.7 pts

97th pct

Capital efficiency

+0.7 pts

57th pct

Profitability

+0.6 pts

54th pct

Scale

-0.6 pts

46th pct

Shareholder dilution

-1.3 pts

24th pct

Institutional flow

-1.3 pts

24th pct

Earnings growth

-1.9 pts

12th pct

Latest change (2026-08-06): 61 → 58 · ↓ Revenue growth 78→64; ↓ Earnings growth 65→20; despite ↑ Profit margin 47→60

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

COLL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for COLLEGIUM PHARMACEUTICAL, INC (COLL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COLL at 62.7/100 on a 32-signal composite quality model, placing it at rank #692 of 2,962 stocks — the top 25% of the AI-ranked universe. COLL scores in the top quartile across earnings quality (97.4), free cash flow (91.0), revenue growth (77.7). Areas of concern include institutional flow (23.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), COLLEGIUM PHARMACEUTICAL, INC reports quarterly revenue of $199.9M, net income of $-15.1M, free cash flow of $70.8M. Top institutional holders of COLL by reported 13-F value include BlackRock, Jupiter Topco, Invesco Ltd., based on the most recent SEC filings. COLL trades on the Nasdaq exchange and files with the SEC under CIK 1267565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COLL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COLLEGIUM PHARMACEUTICAL, INC directly from SEC EDGAR. COLLEGIUM PHARMACEUTICAL, INC's 13F Pro composite quality score has ranged between 35 and 72 since 2021, currently 62.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$199.9M

Net Income

Q2 2026

$-15.1M

Free Cash Flow

Q2 2026

$70.8M

ROIC

Q2 2026

4.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+23.6% YoY

$780.6MFY 2025

FY22 $463.9MFY23 $566.8MFY24 $631.4MFY25 $780.6M

Net Income

-9.1% YoY

$62.9MFY 2025

FY22 $-25.0MFY23 $48.2MFY24 $69.2MFY25 $62.9M

Operating Income

+5.7% YoY

$179.6MFY 2025

FY22 $33.3MFY23 $167.0MFY24 $169.9MFY25 $179.6M

EPS (Diluted)

-7.0% YoY

$1.73FY 2025

FY22 $-0.74FY23 $1.29FY24 $1.86FY25 $1.73

Total Assets

-0.4% YoY

$1.66BFY 2025

FY22 $1.17BFY23 $1.14BFY24 $1.66BFY25 $1.66B

Op. Cash Flow

+60.7% YoY

$329.3MFY 2025

FY22 $124.2MFY23 $274.7MFY24 $205.0MFY25 $329.3M

Free Cash Flow

+61.1% YoY

$327.6MFY 2025

FY22 $122.6MFY23 $274.3MFY24 $203.3MFY25 $327.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$780.6M +23.6%	$631.4M +11.4%	$566.8M +22.2%	$463.9M +67.6%	$276.9M -10.7%	$310.0M
Net Income	$62.9M -9.1%	$69.2M +43.7%	$48.2M +292.6%	$-25.0M -135.0%	$71.5M +167.3%	$26.8M
Operating Income	$179.6M +5.7%	$169.9M +1.8%	$167.0M +401.1%	$33.3M +89.0%	$17.6M -68.7%	$56.2M
EPS (Diluted)	$1.73 -7.0%	$1.86 +44.2%	$1.29 +274.3%	$-0.74 -139.8%	$1.86 +144.7%	$0.76
Total Assets	$1.66B -0.4%	$1.66B +45.5%	$1.14B -2.6%	$1.17B +69.7%	$692.1M +7.5%	$643.8M
Operating Cash Flow	$329.3M +60.7%	$205.0M -25.4%	$274.7M +121.2%	$124.2M +20.0%	$103.6M +10.2%	$93.9M
Free Cash Flow	$327.6M +61.1%	$203.3M -25.9%	$274.3M +123.7%	$122.6M +20.7%	$101.6M +15.0%	$88.4M

Get alerted when COLL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for COLLEGIUM PHARMACEUTICAL, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COLL

BlackRock, Inc.
$197.0M5,441,202 sh
Jupiter Topco LLC
$77.7M2,147,072 sh
Invesco Ltd.
$68.1M1,882,499 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$59.1M1,632,781 sh
PRINCIPAL FINANCIAL GROUP INC
$59.1M1,632,360 sh
STATE STREET CORP
$55.3M1,528,881 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$50.9M1,405,567 sh
VANGUARD CAPITAL MANAGEMENT LLC
$50.0M1,381,261 sh
RENAISSANCE TECHNOLOGIES LLC
$49.5M1,366,549 sh
EVENTIDE ASSET MANAGEMENT, LLC
$49.3M1,361,228 sh

Fund	Value	Shares
BlackRock, Inc.	$197.0M	5,441,202
Jupiter Topco LLC	$77.7M	2,147,072
Invesco Ltd.	$68.1M	1,882,499
FULLER & THALER ASSET MANAGEMENT, INC.	$59.1M	1,632,781
PRINCIPAL FINANCIAL GROUP INC	$59.1M	1,632,360
STATE STREET CORP	$55.3M	1,528,881
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$50.9M	1,405,567
VANGUARD CAPITAL MANAGEMENT LLC	$50.0M	1,381,261
RENAISSANCE TECHNOLOGIES LLC	$49.5M	1,366,549
EVENTIDE ASSET MANAGEMENT, LLC	$49.3M	1,361,228

Companies Similar to COLL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 25 shared holders

Rubric Capital Management LP LOOMIS SAYLES & CO L P Artemis Investment Management LLP

Pediatrix Medical Group, Inc.

AI score

Shared smart-money ownership · 24 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.LSV ASSET MANAGEMENT ROYCE & ASSOCIATES LP

AMPH

Amphastar Pharmaceuticals, Inc.

AI score

Similar quality profile · 13 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.LSV ASSET MANAGEMENT ROYCE & ASSOCIATES LP

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 22 shared holders

LSV ASSET MANAGEMENT ROYCE & ASSOCIATES LP Brandywine Global Investment Management, LLC

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 8 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC

PCRX

Pacira BioSciences, Inc.

AI score

Similar quality profile · 14 shared holders

LSV ASSET MANAGEMENT Hillsdale Investment Management Inc.WEDGE CAPITAL MANAGEMENT L L P/NC

INVA

Innoviva, Inc.

AI score

Shared smart-money ownership · 24 shared holders

ROYCE & ASSOCIATES LP Uniplan Investment Counsel, Inc.Brandywine Global Investment Management, LLC

RGEN

REPLIGEN CORP

AI score

Similar quality profile · 7 shared holders

LOOMIS SAYLES & CO L P ROYCE & ASSOCIATES LP PEREGRINE CAPITAL MANAGEMENT LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COLL on your watchlist

Track score changes the day COLLEGIUM PHARMACEUTICAL, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COLL a good stock to buy?

13F Pro's AI-powered analysis of COLLEGIUM PHARMACEUTICAL, INC (COLL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COLL are available on the COLL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. COLL is classified as a small company.

Which hedge funds own COLL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COLL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of COLLEGIUM PHARMACEUTICAL, INC's investment landscape.